Immune Gene Expression Analysis of Bladder Carcinoma in-situ and Correlation with CK20 Immunohistochemical Staining and Response to BCG Treatment

被引：0
|
作者：
Lombardo, Kara [1 ]
Amador, Belkiss Murati [2 ]
Parimi , Vamsi [3 ]
McGuire, Bridget [4 ]
Matoso, Andres [1 ]
机构：
[1] Johns Hopkins Med Inst, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[3] Johns Hopkins Univ, Sch Med, Elkridge, MD USA
[4] Johns Hopkins Univ, Sch Med, Greenberg Bladder Canc Inst, Baltimore, MD USA
来源：
LABORATORY INVESTIGATION | 2020年 / 100卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
960
引用
收藏
页码：924 / 925
页数：2
相关论文
共 50 条
  • [41] The Utility of AMACR as a Diagnostic Marker for Urothelial Carcinoma In Situ, a Study Supported by Morphometric Image Analysis and Triple Immunohistochemical Panel [CK 20, CD44 and p53]
    Kamel, Nora N.
    Elalfy, Zahraa S.
    Anis, Shady E.
    Farrag, AbdelRazik H.
    Abdel-Aal, Wafaa E.
    Salem, Samira A. M.
    Ishak, Elia A.
    LABORATORY INVESTIGATION, 2017, 97 : 233A - 234A
  • [42] CLASS-I AND CLASS-II HLA-ANTIGEN EXPRESSION BY TRANSITIONAL CELL-CARCINOMA OF THE BLADDER - CORRELATION WITH T-CELL INFILTRATION AND BCG TREATMENT
    STEFANINI, GF
    BERCOVICH, E
    MAZZEO, V
    GRIGIONI, WF
    EMILI, E
    DERRICO, A
    LOCIGNO, M
    TAMAGNINI, N
    MAZZETTI, M
    JOURNAL OF UROLOGY, 1989, 141 (06): : 1449 - 1453
  • [43] Expression of a-Methylacyl-CoA Racemase (AMACR) in Urothelial Carcinoma In Situ (CIS): Comparative Utility with More Traditional Markers (CK20,CD445,p53) in the Distinction of Urothelial CIS and Reactive Urothelial Atypia
    Aron, M.
    Luthringer, D. J.
    McKenney, J. K.
    Hansel, D. E.
    Westfall, D. E.
    Parkh, R.
    Vankalakunti, M.
    Mohanty, S. K.
    Balzer, B. L.
    Amin, M. B.
    LABORATORY INVESTIGATION, 2012, 92 : 190A - 190A
  • [44] AN INTERIM ANALYSIS OF A PHASE II CLINICAL STUDY OF INTRAVESICAL PHOTO DYNAMIC THERAPY IN PATIENTS WITH BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CARCINOMA IN-SITU (CIS)
    Kulkarni, Girish
    Richards, Kyle
    Black, Peter C.
    Rendon, Ricardo
    Chin, Joseph
    Shore, Neal
    Jayram, Gautam
    Kramolowsky, Eugene
    Saltzstein, Daniel
    Agarwal, Piyush
    Belkoff, Laurence
    O'Donnell, Michael
    Kamat, Ashish M.
    Zlotta, Alexandre
    Jewett, Michael A. S.
    Lamm, Donald
    DeGruttola, Victor
    Mandel, Arkady
    Dumoulin-White, Roger J.
    Kassouf, Wassim
    JOURNAL OF UROLOGY, 2023, 209 : E871 - E871
  • [45] Expression of a-Methylacyl-CoA Racemase (AMACR) in Urothelial Carcinoma In Situ (CIS): Comparative Utility with More Traditional Markers (CK20,CD44s,p53) in the Distinction of Urothelial CIS and Reactive Urothelial Atypia
    Aron, M.
    Luthringer, D. J.
    McKenney, J. K.
    Hansel, D. E.
    Westfall, D. E.
    Parkh, R.
    Vankalakunti, M.
    Mohanty, S. K.
    Balzer, B. L.
    Amin, M. B.
    MODERN PATHOLOGY, 2012, 25 : 190A - 190A
  • [46] Immunohistochemical expression of the receptor tyrosine kinase axl/ufo in normal breast epithelium (BE), ductal carcinoma in-situ (DCIS) and invasive ductal breast cancer (IDC): correlation with receptor expression, bone marrow micrometastasis and survival.
    Braun, S
    Hutterer, A
    Knyazev, P
    Seeber, J
    Mueller-Holzner, E
    Marth, C
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S250 - S250
  • [47] EVALUATION OF PAP AND PSA GENE-EXPRESSION IN PROSTATIC HYPERPLASIA AND PROSTATIC-CARCINOMA USING NORTHERN-BLOT ANALYSES, IN-SITU HYBRIDIZATION AND IMMUNOHISTOCHEMICAL STAININGS WITH MONOCLONAL AND BISPECIFIC ANTIBODIES
    HAKALAHTI, L
    VIHKO, P
    HENTTU, P
    AUTIOHARMAINEN, H
    SOINI, Y
    VIHKO, R
    INTERNATIONAL JOURNAL OF CANCER, 1993, 55 (04) : 590 - 597
  • [48] Comparative Analysis of Four Immunohistochemical Assays for HER2 Expression in Breast Carcinoma - Correlation with HER2 Gene Amplification and Perspectives for HER2 Low Expression
    Nielsen, Soren
    Wang, Diana
    Calero, Valeria Montalvo
    LaMar, Jared
    Saxena, Ashish
    Decamillis, Rina
    Stensballe, Mia
    LABORATORY INVESTIGATION, 2023, 103 (03) : S192 - S192
  • [49] Long-term oncological outcomes of bladder Carcinoma In Situ (CIS) treated with BCG immunotherapy: Prognostic implications of 6-month pathological response assessed by a propensity score matching analysis
    Subiela, Henriquez J. D.
    Rodriguez-Faba, O.
    Aumatell, J.
    Calderon, J.
    Mercade, A.
    Balana, J.
    Esquinas, C.
    Parada, R.
    Huguet, J.
    Algaba, F.
    Breda, A.
    Palou, J.
    EUROPEAN UROLOGY, 2021, 79 : S1065 - S1065
  • [50] High systemic immune-inflammation index predicts poor prognosis and response to intravesical BCG treatment in patients with urothelial carcinoma: a systematic review and meta-analysis
    Liu, Wen
    Zhang, Yixuan
    Wang, Miaomiao
    Wang, Miao
    Yang, Qingya
    FRONTIERS IN ONCOLOGY, 2023, 13
12345